Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

Trading Update

16 Feb 2021 07:00

RNS Number : 1775P
Calnex Solutions PLC
16 February 2021
 

This announcement contains inside information.

 

16 February 2021

 

Calnex Solutions plc

("Calnex", the "Company" or the "Group")

 

Trading Update

Calnex Solutions plc (AIM: CLX), an established provider of test and measurement solutions for the global telecommunications sector, today provides an update on trading for the year ending 31 March 2021 ("FY21").

 

The Board is pleased to announce that the strong levels of customer spend experienced in the first half of the Group's financial year continued into the second half of FY21, with no deterioration in operational performance noted from any macro-economic factors, including the ongoing COVID-19 pandemic. The Board believes the COVID-19 pandemic may have influenced certain customers' spending patterns, resulting in some revenues being brought forward into FY21.

 

As a result of the continued strong performance in the second half of FY21, the Board anticipates revenues for FY21 will be ahead of market expectations. In addition, as a result of lower travel and event costs due to COVID-19 restrictions, higher margins are expected to be achieved in FY21 than would have been anticipated, which will result in the Company's profitability also being ahead of market expectations in FY21.

 

With the long-term underlying growth drivers continuing, as the market transitions to 5G and the widescale adoption of cloud computing progresses, the Board is confident that while industry spending patterns may normalise in FY22, Calnex is well positioned to deliver its historical growth rates over the long-term.

 

The Group expects to commence FY22 with a healthy order book and intends to provide an update on the outlook for FY22 when it announces its preliminary results for FY21 in late May.

 

Tommy Cook, Chief Executive Officer and founder of Calnex, said:

 

"We have seen the strong customer spending patterns flagged at the time of our interim results continue into the second half of the year, which coupled with our continued strong operational performance means we are pleased to confirm that we expect to deliver growth in the year considerably ahead of the forecasts published at the time of our IPO. While we have now started to see some signs that this early pull through of orders is reverting to more normal levels, we anticipate entering FY22 with a healthy order book."

 

"We continue to make good progress executing on our growth strategy, investing in our product offering and people to capitalise on the growth of the telecoms testing market as the industry transitions to 5G and the cloud computing sector continues to grow. We are delighted to have delivered this strong performance in our first period as a PLC and continue to look to the future with confidence."

 

For more information, please contact:

 

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

 

 

 

Cenkos Securities plc - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

 

 

Alma PR

+ 44(0) 20 3405 0213

Caroline Forde, Harriet Jackson, Joe Pederzolli

 

 

 

Overview of Calnex

 

Calnex designs, produces and markets test instrumentation and solutions for network synchronization and network emulation, enabling its customers to validate the performance of the critical infrastructure associated with telecoms networks. To date, Calnex has secured and delivered orders to over 600 customer sites in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Facebook.

 

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSTFDIELIL
Date   Source Headline
1st Jun 20267:30 amRNSDirector Dealing
29th May 20263:00 pmRNSExercise of Options and Total Voting Rights
26th May 20267:00 amRNSFinal Results
14th May 20267:00 amRNSNotice of Presentations
13th Apr 20267:00 amRNSFY26 Trading Update and Notice of Results
30th Mar 20267:00 amRNSHolding(s) in Company
26th Nov 20257:30 amRNSDirector Dealing
18th Nov 20257:00 amRNSInterim Results
6th Nov 202511:30 amRNS-RCalnex and Viavi Partnership
30th Oct 20257:00 amRNSNotice of Results and Presentations
8th Oct 20252:08 pmRNSExercise of Options and Total Voting Rights
16th Sep 20259:09 amRNSExercise of Options and Total Voting Rights
14th Aug 20254:12 pmRNSResult of AGM
14th Aug 20257:00 amRNSAGM Statement
15th Jul 20257:00 amRNSNotice of AGM and posting of Annual Report
16th Jun 20259:52 amRNSLong-Term Incentive Plan Awards
10th Jun 202511:59 amRNSDirector Dealing
20th May 20257:00 amRNSFinal Results
15th May 20257:00 amRNSNotice of Investor Presentation
8th Apr 20257:00 amRNSFY25 Trading Update and Notice of Results
14th Mar 20257:00 amRNSDirector Dealing
29th Jan 202510:48 amRNSExercise of Options
19th Nov 20247:00 amRNSInterim Results
4th Nov 20247:00 amRNSNotice of Results and Investor Presentation
8th Oct 20247:00 amRNSDirector/PDMR Dealing
2nd Oct 20244:57 pmRNSResult of General Meeting
6th Sep 20247:00 amRNSNotice of General Meeting
22nd Aug 20245:18 pmRNSResult of AGM
22nd Aug 20247:00 amRNSAGM Statement
18th Jul 20249:08 amRNSNotice of AGM
17th Jul 20242:00 pmRNSLong-Term Incentive Plan Awards
21st May 20247:00 amRNSFY24 Final Results
10th Apr 20247:00 amRNSNotice of Investor Presentation
3rd Apr 20247:00 amRNSFY24 Trading Update and Notice of Results
21st Feb 20249:28 amRNSExercise of Options
14th Feb 20241:08 pmRNSExercise of Options
12th Dec 20233:47 pmRNSPDMR Dealings
21st Nov 20237:00 amRNSInterim Results
1st Nov 202312:24 pmRNSChange of Nominated Adviser
26th Oct 20237:00 amRNSNotice of Investor Presentation
10th Oct 20233:17 pmRNSTrading Update and Notice of Results
25th Aug 20234:36 pmRNSPDMR Dealings
16th Aug 20231:22 pmRNSResult of AGM
16th Aug 20237:00 amRNSAGM Statement
11th Aug 20232:00 pmRNSLong-Term Incentive Plan Awards
17th Jul 20237:00 amRNSNotice of AGM
12th Jul 202312:05 pmRNSDirector/PDMR Dealings
12th Jun 20234:34 pmRNSPDMR Dealings
23rd May 20237:00 amRNSFY23 Final Results
11th May 20239:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.